[Skip to Content]
[Skip to Content Landing]
Research Letter
January 2019

Cost-Related Insulin Underuse Among Patients With Diabetes

Author Affiliations
  • 1Yale College, New Haven, Connecticut
  • 2Yale School of Medicine, New Haven, Connecticut
  • 3Division of Pharmacoepidemiology and Pharmacoeconomics, Department of Medicine, Brigham and Women’s Hospital, Harvard Medical School, Boston, Massachusetts
  • 4Department of Internal Medicine, Yale School of Medicine, New Haven, Connecticut
JAMA Intern Med. 2019;179(1):112-114. doi:10.1001/jamainternmed.2018.5008

Insulin is lifesaving for people with diabetes and is included on the Model List of Essential Medicines formulated by the World Health Organization.1 This means it should be available at all times at a price the individual and the community can afford.1 However, over the past decade, insulin prices have tripled in the United States, while out-of-pocket costs per prescription doubled.2,3 High costs of medications can contribute to nonadherence,4 but the prevalence of cost-related insulin underuse is unknown.

Limit 200 characters
Limit 25 characters
Conflicts of Interest Disclosure

Identify all potential conflicts of interest that might be relevant to your comment.

Conflicts of interest comprise financial interests, activities, and relationships within the past 3 years including but not limited to employment, affiliation, grants or funding, consultancies, honoraria or payment, speaker's bureaus, stock ownership or options, expert testimony, royalties, donation of medical equipment, or patents planned, pending, or issued.

Err on the side of full disclosure.

If you have no conflicts of interest, check "No potential conflicts of interest" in the box below. The information will be posted with your response.

Not all submitted comments are published. Please see our commenting policy for details.

Limit 140 characters
Limit 3600 characters or approximately 600 words